Gene Bio Tech진바이오텍
086060 · KOSDAQ · ₩086060 · 진바이오텍
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩5,295
vs the current price (₩5,080)
- Enterprise value
- ₩36B
- Equity value
- ₩46B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩2,325
- −54.2%
- Base
- ₩5,295
- +4.2%
- Bull
- ₩10,795
- +112.5%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (4.0%).
Revenue growth
- 3.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.
- 3.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.
- 3.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.
Business
- 4%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 1.7%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 2.2%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 29%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.11%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-28.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.61%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩89B
- Net debt (borrowings and leases − cash and deposits)
- −₩10B
- + Stakes and investments
- ₩69M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 8,610,587
- Share price
- ₩5,080
- Market cap
- ₩44B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩79B | ₩83B | ₩91B | ₩92B | ₩95B | ₩98B | ₩101B | ₩104B |
| Growth | −4.0% | 4.4% | 9.4% | 3.1% | 3.1% | 3.1% | 3.0% | 3.0% |
| EBIT | ₩4B | ₩3.8B | ₩3.9B | ₩3.7B | ₩3.8B | ₩3.9B | ₩4B | ₩4.2B |
| EBIT margin | 5.0% | 4.6% | 4.3% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% |
| After-tax EBIT | ₩2.9B | ₩2.8B | ₩2.8B | ₩2.7B | ₩2.8B | ₩2.8B | ₩2.9B | ₩3B |
| + Depreciation | — | — | — | ₩1.6B | ₩1.6B | ₩1.7B | ₩1.7B | ₩1.8B |
| − Capital spending | ₩767M | ₩1.2B | ₩3.8B | ₩2B | ₩2.1B | ₩2.2B | ₩2.2B | ₩2.3B |
| − Working capital | −₩12B | ₩5.3B | −₩3.1B | ₩803M | ₩828M | ₩853M | ₩852M | ₩877M |
| Free cash flow | — | — | — | ₩1.4B | ₩1.5B | ₩1.5B | ₩1.6B | ₩1.6B |
| Discount factor | — | — | — | 0.931 | 0.867 | 0.807 | 0.751 | 0.700 |
| Present value | — | — | — | ₩1.3B | ₩1.3B | ₩1.2B | ₩1.2B | ₩1.1B |
Terminal value ₩42B, worth ₩29B today: 83% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩6,533 a share)Now 0.78× | ₩3,9160.60× | ₩4,9060.75× | ₩6,1450.94× |
| Price / earnings (last 12 months: ₩426 a share)Now 11.9× | ₩4,0699.54× | ₩4,87511.4× | ₩8,44219.8× |
| P/E on run-rate earnings (Q2 2026 × 4: ₩600 a share)Now 8.46× | ₩5,7269.54× | ₩6,86011.4× | ₩11,87919.8× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | ₩5,923 | ₩6,090 | ₩6,292 | ₩6,543 | ₩6,864 |
| 6.9% | ₩5,486 | ₩5,604 | ₩5,743 | ₩5,910 | ₩6,117 |
| 7.4% | ₩5,119 | ₩5,201 | ₩5,295 | ₩5,407 | ₩5,541 |
| 7.9% | ₩4,805 | ₩4,861 | ₩4,924 | ₩4,997 | ₩5,082 |
| 8.4% | ₩4,535 | ₩4,572 | ₩4,612 | ₩4,657 | ₩4,709 |
Now (TTM)
- Market cap
- ₩44B
- Enterprise value
- ₩34B
- P/E
- 11.9×
- P/B
- 0.8×
- P/S
- 0.5×
- EV/EBITDA
- —
- Dividend yield
- 1.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩4,010 | ₩3,290 | ₩4,360 | ₩3,990 | ₩5,240 |
| Market cap | ₩35B | ₩28B | ₩38B | ₩34B | ₩45B |
| P/E | 9.1× | 9.9× | 14.5× | 22.6× | — |
| P/B | 0.6× | 0.6× | 0.8× | 0.8× | 1.0× |
| P/S | 0.4× | 0.3× | 0.5× | 0.4× | 0.7× |
| EV/EBITDA | — | — | — | — | 52.9× |
| Dividend yield | 1.2% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Gene Bio Tech | 11.9× | 0.8× | 0.5× | — | 1.0% |
| Samsung C&T | 17.5× | 0.5× | 1.1× | — | 0.9% |
| POSCO International | 10.6× | 1.3× | 0.3× | — | 3.7% |
| ISC | 41.4× | 5.5× | 11.5× | — | 0.6% |
| Youngone | 5.1× | 0.7× | 0.7× | — | 3.1% |
| Dong SUH Companies | 19.0× | 1.6× | 5.1× | — | 4.1% |
| Shinsegae | 13.7× | 0.4× | 0.3× | — | 2.1% |
| Similar companies (median) | 15.6× | 1.0× | 0.9× | — | 2.6% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Gene Bio Tech / 진바이오텍 / 086060 / KRX:086060
Source: KRX statistical information